# Clinical observation of posttransplant lymphoproliferative disorder in a single center

## TL;DR

This study examines the clinical features of post-transplant lymphoproliferative disorder in patients who underwent stem cell transplants and evaluates the impact of a new WHO classification system.

## Contribution

The study applies the 2022 WHO-HAEM5 classification to PTLD cases and identifies poor outcomes in patients with severe aplastic anemia.

## Key findings

- Monomorphic PTLD had the worst prognosis with a 54.5% overall survival rate.
- All deaths in monomorphic PTLD cases were linked to severe aplastic anemia or aggressive disease progression.
- Patients with severe aplastic anemia who develop PTLD require more aggressive clinical interventions.

## Abstract

为了分析异基因造血干细胞移植（allo-HSCT）后淋巴增殖性疾病的临床特征并探讨2022年世界卫生组织第五版《造血与淋巴组织肿瘤分类》（WHO-HAEM5）对移植后淋巴增殖性疾病（PTLD）的最新命名方式的临床指导意义，本文回顾性分析中国人民解放军总医院第五医学中心血液病医学部自2016年1月1日至2024年12月15日行allo-HSCT后诊断为PTLD的35例患者临床资料，其中临床诊断11例，病理确诊24例；24例病理确诊的PTLD按WHO-HAEM5最新命名方式重新命名。单形性PTLD，对应淋巴瘤亚型PTLD，该组患者预后最差，总生存率仅为54.5％（6/11），死亡患者原发病均为重型再生障碍性贫血（SAA），1例死于化疗相关并发症，其余4例均死于PTLD爆发式进展。原发病诊断为SAA的PTLD患者预后差，临床需采取更积极的干预策略。